24 "Breast" clinical trials found.
-
TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
The purpose of this study is to determine whether there is any benefit of regional radiotherapy and to compare good and bad effects of not ... -
A Phase 1b First-in-human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors
If you are diagnosed with stage 4 tumor of any solid origin, for example; breast, endometrial, ovarian, fallopian tube, cervix, vaginal or primary peritoneal cancer ...
-
An Open-label Multicenter Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab a Human Bispecific EGFR and cMet Antibody for the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer
The purpose of the study is to determine the safety and antitumor activity of amivantamab delivered subcutaneously (SC) or under the skin with and without ... -
An Open Label Phase 1 Dose-Escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 with Pembrolizumab Following Radiation Therapy in the Treatment of Non-Small-Cell Lung Cancer Triple-Negative Breast Cancer or Squamous Cell Carcinoma of the Head and Neck that has Progressed on Checkpoint Inhibitors
The purpose of the study is to evaluate the safety, tolerability, and preliminary antitumor activity of TAK-676 and pembrolizumab following radiation therapy in the treatment ... -
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
The purpose of the study is to look at safety and efficacy of study drug ABBV-151 alone and in combination with study drug ABBV-181. We ... -
A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug ... -
A Phase 1 Open Label Dose-Escalation and Expansion Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors
The purpose of the study is to determine the recommended Phase 2 dose of ORIN1001 when given as a single agent as well as phase ... -
PHASE 1/2A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
The purpose of the study is to investigate the safety, tolerability of study drug PF-07104091, a CDK2 inhibitor, when administered as a single agent and ...
-
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ... -
Phase 1 Open-Label Multicenter Dose Escalation Study of mRNA-2752 a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L IL-23 and IL-36? for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
The purpose of the study is to evaluate the anti-tumor activity of ITu injections of mRNA-2752 alone and in combination with intravenously administered durvalumab in ...